<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="75">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on August 12, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04388527</url>
  </required_header>
  <id_info>
    <org_study_id>842996 (PennCCP-01)</org_study_id>
    <nct_id>NCT04388527</nct_id>
  </id_info>
  <brief_title>COVID-19 Convalescent Plasma for Mechanically Ventilated Population</brief_title>
  <official_title>An Open-Label, Single Arm, Phase 1, Safety and Exploratory Efficacy Study of Convalescent Plasma for Severely Ill Mechanically Ventilated Participants With COVID-19 Caused by SARS-CoV-2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if this plasma can be safely used in humans with COVID-19&#xD;
      and to see if it can improve patients' health when they are sick with COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This open-label, single arm, phase 1 trial will assess the safety and efficacy of&#xD;
      convalescent plasma in severely ill, mechanically ventilated participants with pneumonia due&#xD;
      to COVID-19. This study will enroll adults 18 years old and older, including pregnant women.&#xD;
      A total of 50 eligible participants will receive 2 units of convalescent plasma collected&#xD;
      from ABO-compatible donors who have recovered from COVID-19. Participants will receive&#xD;
      convalescent plasma on Study Day 1 in addition to standard of care. Participants will be&#xD;
      assessed daily while hospitalized and then on Study Days 15, 22, 29, and 60. All participants&#xD;
      will undergo a series of safety, efficacy, and laboratory assessments. Blood samples will be&#xD;
      collected on Days 1 (prior to plasma administration), 3, 5, 8, 11, 15, 29, and 60.&#xD;
      Oropharyngeal or endotracheal samples will be collected on Days 1 (prior to plasma&#xD;
      administration), 3, 5, 8, 11, and 15.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 30, 2020</start_date>
  <completion_date type="Actual">January 30, 2021</completion_date>
  <primary_completion_date type="Actual">January 25, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participants With Serious Adverse Events.</measure>
    <time_frame>Up to Study Day 29</time_frame>
    <description>Cumulative incidence of participants with at least one serious adverse events (SAEs) at Study Day 29.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Clinical Improvement.</measure>
    <time_frame>Up to Study Day 29</time_frame>
    <description>Time to removal from mechanical ventilation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Status Assessment, Using 8-point Ordinal Scale, of Convalescent Plasma Administration</measure>
    <time_frame>Up to Study Day 29</time_frame>
    <description>Time to improvement by at least 2 category from Day 1 (time to reach WHO8 &lt;=5). WHO8 score:&#xD;
Not hospitalized, no limitations on activities.&#xD;
Not hospitalized, limitation on activities and/or requiring home oxygen;&#xD;
Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care;&#xD;
Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise);&#xD;
Hospitalized, requiring supplemental oxygen;&#xD;
Hospitalized, on non-invasive ventilation or high flow oxygen devices;&#xD;
Hospitalized, on invasive mechanical ventilation or ECMO;&#xD;
Death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Status Assessment Using the National Early Warning Score (NEWS) of Convalescent Plasma Administration</measure>
    <time_frame>Up to Study Day 29</time_frame>
    <description>Time to discharge or to a NEWS of â‰¤ 2 and maintained for 24 hours, whichever occurs first.&#xD;
NEWS assessed daily while hospitalized until discharge or death and on Days 15 and 29.&#xD;
Higher NEWS is worse, range from 0 to 20.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of New Oxygenation Use up to Day 29 of Convalescent Plasma Administration</measure>
    <time_frame>From enrollment to Day 29.</time_frame>
    <description>Incidence of new oxygenation use up to Day 29.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of New Oxygen Use up to Day 29 of Convalescent Plasma Administration</measure>
    <time_frame>From enrollment to Day 29.</time_frame>
    <description>Days of new oxygen use up to Day 29.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygenation</measure>
    <time_frame>Daily while hospitalized up to Study Day 29.</time_frame>
    <description>Days of supplemental oxygen while in hospital up to Study Day 29. In hospital supplemental oxygen days counted as days with a WHO8 ordinal score of 5, 6, or 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-invasive Ventilation/High Flow Oxygen Days up to Day 29 of Convalescent Plasma Administration.</measure>
    <time_frame>Daily while in hospital to Study Day 29.</time_frame>
    <description>Days of non-invasive ventilation/high flow oxygen while in hospital up to Day 29, defined as having WHO8 ordinal score of 6 = Hospitalized, on non-invasive ventilation or high flow oxygen devices</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With at Least One Day of Non-invasive Ventilation/High Flow Oxygen up to Day 29 of Convalescent Plasma Administration.</measure>
    <time_frame>Daily while in hospital to Study Day 29.</time_frame>
    <description>Number of subjects with at least one day of non-invasive ventilation (WHO8 ordinal score of 6) while in hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Non-invasive Ventilation/High Flow Oxygen up to Day 29 of Convalescent Plasma Administration.</measure>
    <time_frame>Daily while in hospital to Study Day 29.</time_frame>
    <description>Days of non-invasive ventilation/high flow oxygen up to Day 29.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Invasive Ventilation/ Extracorporeal Membrane Oxygenation(ECMO) Days</measure>
    <time_frame>Daily while in hospital to Study Day 29</time_frame>
    <description>Days on Invasive Ventilator/ECMO defined as WHO8 ordinal score of 7 = Hospitalized, on invasive mechanical ventilation or ECMO</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of New Mechanical Ventilation or ECMO Use of Convalescent Plasma Administration.</measure>
    <time_frame>From enrollment to Day 29.</time_frame>
    <description>Incidence of new mechanical ventilation or ECMO use up to Day 29.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of New Mechanical Ventilation or ECMO Use of Convalescent Plasma Administration.</measure>
    <time_frame>From enrollment to Day 29.</time_frame>
    <description>Days of new mechanical ventilation or ECMO use up to Day 29.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Hospitalization</measure>
    <time_frame>To Study Day 29</time_frame>
    <description>Duration (days) of first hospitalization. Time until death or discharge or Study Day 29</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>28 days from Study Day 1</time_frame>
    <description>28 day mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events (SAEs) Through Day 29 of Convalescent Plasma Administration.</measure>
    <time_frame>Through Study Day 29.</time_frame>
    <description>subjects with Serious Adverse Events (SAEs) through Day 29.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With at Least One Grade 3 and Grade 4 Clinical and/or Laboratory Adverse Events Through Day 29 of Convalescent Plasma Administration.</measure>
    <time_frame>Through Study Day 29</time_frame>
    <description>Number of subjects with at least one Grade 3 or Grade 4 clinical and/or laboratory adverse events through Day 29.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in WBC With Differential Through Day 29 of Convalescent Plasma Administration.</measure>
    <time_frame>Through Day 29.</time_frame>
    <description>Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value &gt; baseline lab value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Hemoglobin Measurement Through Day 29 of Convalescent Plasma Administration.</measure>
    <time_frame>Through Day 29.</time_frame>
    <description>Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value &gt; baseline lab value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Platelets Measurement Through Day 29 of Convalescent Plasma Administration.</measure>
    <time_frame>Through Day 29.</time_frame>
    <description>Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value &gt; baseline lab value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Creatinine Measurement Through Day 29 of Convalescent Plasma Administration.</measure>
    <time_frame>Through Day 29.</time_frame>
    <description>Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value &gt; baseline lab value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Glucose Measurement Through Day 29 of Convalescent Plasma Administration.</measure>
    <time_frame>Through Day 29.</time_frame>
    <description>Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value &gt; baseline lab value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Total Bilirubin Measurement Through Day 29 of Convalescent Plasma Administration.</measure>
    <time_frame>Through Day 29.</time_frame>
    <description>Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value &gt; baseline lab value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in ALT Measurement Through Day 29 of Convalescent Plasma Administration.</measure>
    <time_frame>Through Day 29.</time_frame>
    <description>Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value &gt; baseline lab value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in AST Measurement Through Day 29 of Convalescent Plasma Administration.</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value &gt; baseline lab value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in PT Measurement Through Day 29 of Convalescent Plasma Administration.</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value &gt; baseline lab value.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Covid-19</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Penn COVID-19 convalescent plasma</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>COVID-19 Convalescent Plasma</intervention_name>
    <description>Participants will receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult â‰¥18 years of age&#xD;
&#xD;
          2. Laboratory-confirmed SARS-CoV-2 infection as determined by PCR or other authorized or&#xD;
             approved assay in any specimen collected within 72 hours prior to enrollment. Note -&#xD;
             An exception must be requested to the Sponsor ifâ‰¥72 hours since positive test.&#xD;
&#xD;
          3. Hospitalized, on invasive mechanical ventilation or ECMO, consistent with a clinical&#xD;
             status assessment 8-point ordinal scale severity score of 7.&#xD;
&#xD;
          4. Documentation of pneumonia with radiographic evidence of infiltrates by imaging (e.g.,&#xD;
             chest x-ray or CT scan).&#xD;
&#xD;
          5. Patient or proxy is willing and able to provide written informed consent and comply&#xD;
             with all protocol requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Contraindication to transfusion (e.g., severe volume overload, history of severe&#xD;
             allergic reaction to blood products), as judged by the investigator.&#xD;
&#xD;
          2. Clinical suspicion that the etiology of acute illness (acute decompensation) is&#xD;
             primarily due to a condition other than COVID-19&#xD;
&#xD;
          3. Receipt of other investigational therapy as a part of another clinical trial. a. Note:&#xD;
             investigational therapies used as part of clinical care, (eg, remdesivir,&#xD;
             hydroxychloroquine) are permissible.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katharine J. Bar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2022</verification_date>
  <study_first_submitted>May 4, 2020</study_first_submitted>
  <study_first_submitted_qc>May 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2020</study_first_posted>
  <results_first_submitted>March 10, 2022</results_first_submitted>
  <results_first_submitted_qc>March 31, 2022</results_first_submitted_qc>
  <results_first_posted type="Actual">April 4, 2022</results_first_posted>
  <last_update_submitted>March 31, 2022</last_update_submitted>
  <last_update_submitted_qc>March 31, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 28, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/27/NCT04388527/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment</title>
          <description>Penn COVID-19 convalescent plasma&#xD;
COVID-19 Convalescent Plasma: Participants will receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment</title>
          <description>Penn COVID-19 convalescent plasma&#xD;
COVID-19 Convalescent Plasma: Participants will receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Participants With Serious Adverse Events.</title>
        <description>Cumulative incidence of participants with at least one serious adverse events (SAEs) at Study Day 29.</description>
        <time_frame>Up to Study Day 29</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Penn COVID-19 convalescent plasma&#xD;
COVID-19 Convalescent Plasma: Participants will receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Serious Adverse Events.</title>
          <description>Cumulative incidence of participants with at least one serious adverse events (SAEs) at Study Day 29.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Clinical Improvement.</title>
        <description>Time to removal from mechanical ventilation.</description>
        <time_frame>Up to Study Day 29</time_frame>
        <population>excludes those without improvement (were still on mechanical ventilation or died before removal of invasive mechanical ventilation/ECMO)</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Penn COVID-19 convalescent plasma&#xD;
COVID-19 Convalescent Plasma: Participants will receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Clinical Improvement.</title>
          <description>Time to removal from mechanical ventilation.</description>
          <population>excludes those without improvement (were still on mechanical ventilation or died before removal of invasive mechanical ventilation/ECMO)</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="5" upper_limit="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Status Assessment, Using 8-point Ordinal Scale, of Convalescent Plasma Administration</title>
        <description>Time to improvement by at least 2 category from Day 1 (time to reach WHO8 &lt;=5). WHO8 score:&#xD;
Not hospitalized, no limitations on activities.&#xD;
Not hospitalized, limitation on activities and/or requiring home oxygen;&#xD;
Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care;&#xD;
Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise);&#xD;
Hospitalized, requiring supplemental oxygen;&#xD;
Hospitalized, on non-invasive ventilation or high flow oxygen devices;&#xD;
Hospitalized, on invasive mechanical ventilation or ECMO;&#xD;
Death</description>
        <time_frame>Up to Study Day 29</time_frame>
        <population>excludes those without improvement (WHO8 score of 6,7,or 8)</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Penn COVID-19 convalescent plasma&#xD;
COVID-19 Convalescent Plasma: Participants will receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Status Assessment, Using 8-point Ordinal Scale, of Convalescent Plasma Administration</title>
          <description>Time to improvement by at least 2 category from Day 1 (time to reach WHO8 &lt;=5). WHO8 score:&#xD;
Not hospitalized, no limitations on activities.&#xD;
Not hospitalized, limitation on activities and/or requiring home oxygen;&#xD;
Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care;&#xD;
Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise);&#xD;
Hospitalized, requiring supplemental oxygen;&#xD;
Hospitalized, on non-invasive ventilation or high flow oxygen devices;&#xD;
Hospitalized, on invasive mechanical ventilation or ECMO;&#xD;
Death</description>
          <population>excludes those without improvement (WHO8 score of 6,7,or 8)</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" lower_limit="6" upper_limit="16.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Status Assessment Using the National Early Warning Score (NEWS) of Convalescent Plasma Administration</title>
        <description>Time to discharge or to a NEWS of â‰¤ 2 and maintained for 24 hours, whichever occurs first.&#xD;
NEWS assessed daily while hospitalized until discharge or death and on Days 15 and 29.&#xD;
Higher NEWS is worse, range from 0 to 20.</description>
        <time_frame>Up to Study Day 29</time_frame>
        <population>excludes 20 subjects who have outcome measure of Infinity as they were never discharged or never had NEWS &lt;=2 while in hospital by Study Day 29</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Penn COVID-19 convalescent plasma&#xD;
COVID-19 Convalescent Plasma: Participants will receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Status Assessment Using the National Early Warning Score (NEWS) of Convalescent Plasma Administration</title>
          <description>Time to discharge or to a NEWS of â‰¤ 2 and maintained for 24 hours, whichever occurs first.&#xD;
NEWS assessed daily while hospitalized until discharge or death and on Days 15 and 29.&#xD;
Higher NEWS is worse, range from 0 to 20.</description>
          <population>excludes 20 subjects who have outcome measure of Infinity as they were never discharged or never had NEWS &lt;=2 while in hospital by Study Day 29</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="6" upper_limit="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of New Oxygenation Use up to Day 29 of Convalescent Plasma Administration</title>
        <description>Incidence of new oxygenation use up to Day 29.</description>
        <time_frame>From enrollment to Day 29.</time_frame>
        <population>this endpoint was not measured due to redundancy</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Penn COVID-19 convalescent plasma&#xD;
COVID-19 Convalescent Plasma: Participants will receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of New Oxygenation Use up to Day 29 of Convalescent Plasma Administration</title>
          <description>Incidence of new oxygenation use up to Day 29.</description>
          <population>this endpoint was not measured due to redundancy</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of New Oxygen Use up to Day 29 of Convalescent Plasma Administration</title>
        <description>Days of new oxygen use up to Day 29.</description>
        <time_frame>From enrollment to Day 29.</time_frame>
        <population>this endpoint was not measured due to redundancy</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Penn COVID-19 convalescent plasma&#xD;
COVID-19 Convalescent Plasma: Participants will receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of New Oxygen Use up to Day 29 of Convalescent Plasma Administration</title>
          <description>Days of new oxygen use up to Day 29.</description>
          <population>this endpoint was not measured due to redundancy</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oxygenation</title>
        <description>Days of supplemental oxygen while in hospital up to Study Day 29. In hospital supplemental oxygen days counted as days with a WHO8 ordinal score of 5, 6, or 7.</description>
        <time_frame>Daily while hospitalized up to Study Day 29.</time_frame>
        <population>All 32 enrolled subjects were evaluated for days of oxygenation.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Penn COVID-19 convalescent plasma&#xD;
COVID-19 Convalescent Plasma: Participants will receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19.</description>
          </group>
        </group_list>
        <measure>
          <title>Oxygenation</title>
          <description>Days of supplemental oxygen while in hospital up to Study Day 29. In hospital supplemental oxygen days counted as days with a WHO8 ordinal score of 5, 6, or 7.</description>
          <population>All 32 enrolled subjects were evaluated for days of oxygenation.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" lower_limit="7" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-invasive Ventilation/High Flow Oxygen Days up to Day 29 of Convalescent Plasma Administration.</title>
        <description>Days of non-invasive ventilation/high flow oxygen while in hospital up to Day 29, defined as having WHO8 ordinal score of 6 = Hospitalized, on non-invasive ventilation or high flow oxygen devices</description>
        <time_frame>Daily while in hospital to Study Day 29.</time_frame>
        <population>All 32 enrolled subjects were evaluated. Subjects who never had a WHO8 ordinal score of 6 = Hospitalized, on non-invasive ventilation or high flow oxygen devices have a measured outcome of 0 days.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Penn COVID-19 convalescent plasma&#xD;
COVID-19 Convalescent Plasma: Participants will receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19.</description>
          </group>
        </group_list>
        <measure>
          <title>Non-invasive Ventilation/High Flow Oxygen Days up to Day 29 of Convalescent Plasma Administration.</title>
          <description>Days of non-invasive ventilation/high flow oxygen while in hospital up to Day 29, defined as having WHO8 ordinal score of 6 = Hospitalized, on non-invasive ventilation or high flow oxygen devices</description>
          <population>All 32 enrolled subjects were evaluated. Subjects who never had a WHO8 ordinal score of 6 = Hospitalized, on non-invasive ventilation or high flow oxygen devices have a measured outcome of 0 days.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With at Least One Day of Non-invasive Ventilation/High Flow Oxygen up to Day 29 of Convalescent Plasma Administration.</title>
        <description>Number of subjects with at least one day of non-invasive ventilation (WHO8 ordinal score of 6) while in hospital</description>
        <time_frame>Daily while in hospital to Study Day 29.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Penn COVID-19 convalescent plasma&#xD;
COVID-19 Convalescent Plasma: Participants will receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With at Least One Day of Non-invasive Ventilation/High Flow Oxygen up to Day 29 of Convalescent Plasma Administration.</title>
          <description>Number of subjects with at least one day of non-invasive ventilation (WHO8 ordinal score of 6) while in hospital</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Non-invasive Ventilation/High Flow Oxygen up to Day 29 of Convalescent Plasma Administration.</title>
        <description>Days of non-invasive ventilation/high flow oxygen up to Day 29.</description>
        <time_frame>Daily while in hospital to Study Day 29.</time_frame>
        <population>this endpoint was not measured due to redundancy with other endpoints (#8)</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Penn COVID-19 convalescent plasma&#xD;
COVID-19 Convalescent Plasma: Participants will receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Non-invasive Ventilation/High Flow Oxygen up to Day 29 of Convalescent Plasma Administration.</title>
          <description>Days of non-invasive ventilation/high flow oxygen up to Day 29.</description>
          <population>this endpoint was not measured due to redundancy with other endpoints (#8)</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Invasive Ventilation/ Extracorporeal Membrane Oxygenation(ECMO) Days</title>
        <description>Days on Invasive Ventilator/ECMO defined as WHO8 ordinal score of 7 = Hospitalized, on invasive mechanical ventilation or ECMO</description>
        <time_frame>Daily while in hospital to Study Day 29</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Penn COVID-19 convalescent plasma&#xD;
COVID-19 Convalescent Plasma: Participants will receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19.</description>
          </group>
        </group_list>
        <measure>
          <title>Invasive Ventilation/ Extracorporeal Membrane Oxygenation(ECMO) Days</title>
          <description>Days on Invasive Ventilator/ECMO defined as WHO8 ordinal score of 7 = Hospitalized, on invasive mechanical ventilation or ECMO</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" lower_limit="5.75" upper_limit="19.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of New Mechanical Ventilation or ECMO Use of Convalescent Plasma Administration.</title>
        <description>Incidence of new mechanical ventilation or ECMO use up to Day 29.</description>
        <time_frame>From enrollment to Day 29.</time_frame>
        <population>Endpoint was not well defined as all subjects started on mechanical ventilation</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Penn COVID-19 convalescent plasma&#xD;
COVID-19 Convalescent Plasma: Participants will receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of New Mechanical Ventilation or ECMO Use of Convalescent Plasma Administration.</title>
          <description>Incidence of new mechanical ventilation or ECMO use up to Day 29.</description>
          <population>Endpoint was not well defined as all subjects started on mechanical ventilation</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of New Mechanical Ventilation or ECMO Use of Convalescent Plasma Administration.</title>
        <description>Days of new mechanical ventilation or ECMO use up to Day 29.</description>
        <time_frame>From enrollment to Day 29.</time_frame>
        <population>Endpoint was not well defined as all subjects started on mechanical ventilation</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Penn COVID-19 convalescent plasma&#xD;
COVID-19 Convalescent Plasma: Participants will receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of New Mechanical Ventilation or ECMO Use of Convalescent Plasma Administration.</title>
          <description>Days of new mechanical ventilation or ECMO use up to Day 29.</description>
          <population>Endpoint was not well defined as all subjects started on mechanical ventilation</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Hospitalization</title>
        <description>Duration (days) of first hospitalization. Time until death or discharge or Study Day 29</description>
        <time_frame>To Study Day 29</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Penn COVID-19 convalescent plasma&#xD;
COVID-19 Convalescent Plasma: Participants will receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Hospitalization</title>
          <description>Duration (days) of first hospitalization. Time until death or discharge or Study Day 29</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="9.5" upper_limit="26.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mortality</title>
        <description>28 day mortality</description>
        <time_frame>28 days from Study Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Penn COVID-19 convalescent plasma&#xD;
COVID-19 Convalescent Plasma: Participants will receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19.</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality</title>
          <description>28 day mortality</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serious Adverse Events (SAEs) Through Day 29 of Convalescent Plasma Administration.</title>
        <description>subjects with Serious Adverse Events (SAEs) through Day 29.</description>
        <time_frame>Through Study Day 29.</time_frame>
        <population>.this endpoint is redundant with the primary endpoint</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Penn COVID-19 convalescent plasma&#xD;
COVID-19 Convalescent Plasma: Participants will receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19.</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Adverse Events (SAEs) Through Day 29 of Convalescent Plasma Administration.</title>
          <description>subjects with Serious Adverse Events (SAEs) through Day 29.</description>
          <population>.this endpoint is redundant with the primary endpoint</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With at Least One Grade 3 and Grade 4 Clinical and/or Laboratory Adverse Events Through Day 29 of Convalescent Plasma Administration.</title>
        <description>Number of subjects with at least one Grade 3 or Grade 4 clinical and/or laboratory adverse events through Day 29.</description>
        <time_frame>Through Study Day 29</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Penn COVID-19 convalescent plasma&#xD;
COVID-19 Convalescent Plasma: Participants will receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With at Least One Grade 3 and Grade 4 Clinical and/or Laboratory Adverse Events Through Day 29 of Convalescent Plasma Administration.</title>
          <description>Number of subjects with at least one Grade 3 or Grade 4 clinical and/or laboratory adverse events through Day 29.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in WBC With Differential Through Day 29 of Convalescent Plasma Administration.</title>
        <description>Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value &gt; baseline lab value.</description>
        <time_frame>Through Day 29.</time_frame>
        <population>Defined changes as difference between last measured lab value and baseline (day 1) lab value. Day of last measured lab may differ among subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Penn COVID-19 convalescent plasma&#xD;
COVID-19 Convalescent Plasma: Participants will receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in WBC With Differential Through Day 29 of Convalescent Plasma Administration.</title>
          <description>Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value &gt; baseline lab value.</description>
          <population>Defined changes as difference between last measured lab value and baseline (day 1) lab value. Day of last measured lab may differ among subjects.</population>
          <units>THO/uL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" lower_limit="-4.40" upper_limit="7.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Hemoglobin Measurement Through Day 29 of Convalescent Plasma Administration.</title>
        <description>Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value &gt; baseline lab value.</description>
        <time_frame>Through Day 29.</time_frame>
        <population>Defined changes as difference between last measured lab value and baseline (day 1) lab value. Day of last measured lab may differ among subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Penn COVID-19 convalescent plasma&#xD;
COVID-19 Convalescent Plasma: Participants will receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Hemoglobin Measurement Through Day 29 of Convalescent Plasma Administration.</title>
          <description>Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value &gt; baseline lab value.</description>
          <population>Defined changes as difference between last measured lab value and baseline (day 1) lab value. Day of last measured lab may differ among subjects.</population>
          <units>g/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.65" lower_limit="-2.40" upper_limit="0.475"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Platelets Measurement Through Day 29 of Convalescent Plasma Administration.</title>
        <description>Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value &gt; baseline lab value.</description>
        <time_frame>Through Day 29.</time_frame>
        <population>Defined changes as difference between last measured lab value and baseline (day 1) lab value. Day of last measured lab may differ among subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Penn COVID-19 convalescent plasma&#xD;
COVID-19 Convalescent Plasma: Participants will receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Platelets Measurement Through Day 29 of Convalescent Plasma Administration.</title>
          <description>Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value &gt; baseline lab value.</description>
          <population>Defined changes as difference between last measured lab value and baseline (day 1) lab value. Day of last measured lab may differ among subjects.</population>
          <units>10^3 platelets per uL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" lower_limit="-105.75" upper_limit="90.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Creatinine Measurement Through Day 29 of Convalescent Plasma Administration.</title>
        <description>Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value &gt; baseline lab value.</description>
        <time_frame>Through Day 29.</time_frame>
        <population>Defined changes as difference between last measured lab value and baseline (day 1) lab value. Day of last measured lab may differ among subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Penn COVID-19 convalescent plasma&#xD;
COVID-19 Convalescent Plasma: Participants will receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Creatinine Measurement Through Day 29 of Convalescent Plasma Administration.</title>
          <description>Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value &gt; baseline lab value.</description>
          <population>Defined changes as difference between last measured lab value and baseline (day 1) lab value. Day of last measured lab may differ among subjects.</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.39" lower_limit="-1.505" upper_limit="-0.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Glucose Measurement Through Day 29 of Convalescent Plasma Administration.</title>
        <description>Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value &gt; baseline lab value.</description>
        <time_frame>Through Day 29.</time_frame>
        <population>Defined changes as difference between last measured lab value and baseline (day 1) lab value. Day of last measured lab may differ among subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Penn COVID-19 convalescent plasma&#xD;
COVID-19 Convalescent Plasma: Participants will receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Glucose Measurement Through Day 29 of Convalescent Plasma Administration.</title>
          <description>Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value &gt; baseline lab value.</description>
          <population>Defined changes as difference between last measured lab value and baseline (day 1) lab value. Day of last measured lab may differ among subjects.</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.00" lower_limit="-81.50" upper_limit="-2.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Total Bilirubin Measurement Through Day 29 of Convalescent Plasma Administration.</title>
        <description>Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value &gt; baseline lab value.</description>
        <time_frame>Through Day 29.</time_frame>
        <population>Defined changes as difference between last measured lab value and baseline (day 1) lab value. Day of last measured lab may differ among subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Penn COVID-19 convalescent plasma&#xD;
COVID-19 Convalescent Plasma: Participants will receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Total Bilirubin Measurement Through Day 29 of Convalescent Plasma Administration.</title>
          <description>Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value &gt; baseline lab value.</description>
          <population>Defined changes as difference between last measured lab value and baseline (day 1) lab value. Day of last measured lab may differ among subjects.</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-0.100" upper_limit="0.225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in ALT Measurement Through Day 29 of Convalescent Plasma Administration.</title>
        <description>Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value &gt; baseline lab value.</description>
        <time_frame>Through Day 29.</time_frame>
        <population>Defined changes as difference between last measured lab value and baseline (day 1) lab value. Day of last measured lab may differ among subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Penn COVID-19 convalescent plasma&#xD;
COVID-19 Convalescent Plasma: Participants will receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in ALT Measurement Through Day 29 of Convalescent Plasma Administration.</title>
          <description>Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value &gt; baseline lab value.</description>
          <population>Defined changes as difference between last measured lab value and baseline (day 1) lab value. Day of last measured lab may differ among subjects.</population>
          <units>U/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.00" lower_limit="-20.25" upper_limit="17.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in AST Measurement Through Day 29 of Convalescent Plasma Administration.</title>
        <description>Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value &gt; baseline lab value.</description>
        <time_frame>Through Day 29</time_frame>
        <population>Defined changes as difference between last measured lab value and baseline (day 1) lab value. Day of last measured lab may differ among subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Penn COVID-19 convalescent plasma&#xD;
COVID-19 Convalescent Plasma: Participants will receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in AST Measurement Through Day 29 of Convalescent Plasma Administration.</title>
          <description>Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value &gt; baseline lab value.</description>
          <population>Defined changes as difference between last measured lab value and baseline (day 1) lab value. Day of last measured lab may differ among subjects.</population>
          <units>U/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.50" lower_limit="-33.00" upper_limit="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in PT Measurement Through Day 29 of Convalescent Plasma Administration.</title>
        <description>Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value &gt; baseline lab value.</description>
        <time_frame>Through Day 29</time_frame>
        <population>Defined changes as difference between last measured lab value and baseline (day 1) lab value. Day of last measured lab may differ among subjects.&#xD;
analyzed sample size is 30 because 2 subjects did not have PT lab collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Penn COVID-19 convalescent plasma&#xD;
COVID-19 Convalescent Plasma: Participants will receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in PT Measurement Through Day 29 of Convalescent Plasma Administration.</title>
          <description>Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value &gt; baseline lab value.</description>
          <population>Defined changes as difference between last measured lab value and baseline (day 1) lab value. Day of last measured lab may differ among subjects.&#xD;
analyzed sample size is 30 because 2 subjects did not have PT lab collected.</population>
          <units>seconds</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.050" lower_limit="-2.950" upper_limit="1.075"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 65 days after receiving investigational product</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment</title>
          <description>Penn COVID-19 convalescent plasma&#xD;
COVID-19 Convalescent Plasma: Participants will receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>DAIDS 2.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia (by ECG or physical examination)</sub_title>
                <description>Life-threatening arrhythmia OR Urgent intervention indicated</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <description>Laboratory Value: Chemistries</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Acute CNS Ischemia</sub_title>
                <description>Cerebral vascular accident (e.g., stroke with neurological deficit)</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Altered mental status</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Creatinine Clearance Low</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea or Respiratory Distress</sub_title>
                <counts group_id="E1" events="16" subjects_affected="13" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage (with significant acute blood loss)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <description>Life-threatening embolic event (e.g., pulmonary embolism, thrombus)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>DAIDS 2.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin, Low (g/dL; mmol/L) &gt;= 13 years of age (female only)</sub_title>
                <counts group_id="E1" events="14" subjects_affected="10" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Platelets, Decreased</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hemorrhage (with significant acute blood loss)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hemoglobin, Low (g/dL; mmol/L) &gt;= 13 years of age (male only)</sub_title>
                <counts group_id="E1" events="39" subjects_affected="20" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="13" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever (non-axillary temperatures only)</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALT, High</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>AST, High</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Creatinine, High</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Lactate, High</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Albumin, Low</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Alkalosis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Calcium, Low</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Glucose (mg/dL; mmol/L) Fasting, High</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Sodium, High</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered Mental Status</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Blood Pressure Abnormalities Hypertension (with the lowest reading taken after repeat testing durin</sub_title>
                <counts group_id="E1" events="14" subjects_affected="8" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="13" subjects_affected="8" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Thrombosis or Embolism</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Regulatory Lead</name_or_title>
      <organization>University of Pennsylvania</organization>
      <phone>512-662-4484</phone>
      <email>psom-ind-ide@pobox.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

